According to the recent research report titled ‘Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report By Type; By Application; By End-user; By Regions, Segments & Forecast, 2020 – 2026’, available with Market Study Report, global cancer immunotherapy market is anticipated to reach a valuation of USD 117.82 billion by 2026.
 

Growing number of cancer patients with high mortality rates is one of the key factors driving the growth of global cancer immunotherapy market. According to WHO, cancer was reported to be the second leading cause of deaths in the year 2019, with over one-third of mortalities recorded from cancer owing to tobacco and alcohol consumption, lack of physical activity, high body mass index, along with low fruit & vegetable intake.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2963749/
 

Notably, cancer immunotherapy is used for treating colorectal & other chronic diseases, breast, lung, melanoma, blood cancer, and prostate cancer. Moreover, increasing number of smokers and high air pollution levels worldwide are contributing to global cancer immunotherapy market outlook.
 

In the recent past, cancer immunotherapy has positively influenced oncology sector across the globe, creating lucrative opportunities for the business scenario. Cancer immunotherapy has revolutionized cancer treatment across the globe as compared to current traditional therapies which focuses on relatively long-lived results, high precision and improved survival rates.
 

From regional perspective, Asia Pacific cancer immunotherapy industry is expected to register decent growth over the assessment period, on account of growing population suffering from colorectal and other cancer types along with rising government spending on healthcare infrastructure in Asian economies.
 

As per WHO, over 4 million mortalities from cancer were recorded in the year 2016. In China, cancer is one of the main causes of mortality as 4 million new cancer patients are registered every year. In addition, South Korea has a record of 200,000 new cancer cases registered every year. Lifestyle changes among the population is a leading factor responsible for the increasing number of cancer cases in Asia-Pacific, which in turn is augmenting the regional market share.
 

Leading organizations in global cancer immunotherapy market are OSE Immunotherapeutics, Novartis International AG, Merck and Co. Inc., F.  Hoffmann-La Roche AG, Eli Lilly and Co., Bristol-Myers Squibb, Bayer AG, AstraZeneca PLC, Astellas Pharma, Inc., and Amgen Inc.